Frederick Raal to Oligonucleotides
This is a "connection" page, showing publications Frederick Raal has written about Oligonucleotides.
Connection Strength
2,140
-
Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia. J Clin Lipidol. 2016 Jul-Aug; 10(4):860-869.
Score: 0,521
-
New therapies for reducing low-density lipoprotein cholesterol. Endocrinol Metab Clin North Am. 2014 Dec; 43(4):1007-33.
Score: 0,477
-
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010 Mar 20; 375(9719):998-1006.
Score: 0,344
-
Lomitapide and Mipomersen-Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis. Curr Atheroscler Rep. 2019 11 19; 21(12):48.
Score: 0,168
-
The Effects of Mipomersen on Inhibiting Hepatic VLDL Apolipoprotein B100 Synthesis and Propensity for Hepatic Steatosis. Clin Chem. 2016 08; 62(8):1052-3.
Score: 0,132
-
Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study. Atherosclerosis. 2016 May; 248:238-44.
Score: 0,130
-
Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future. Curr Cardiol Rep. 2015 Nov; 17(11):104.
Score: 0,127
-
Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol. 2015 Mar; 35(3):689-99.
Score: 0,120
-
Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia. J Clin Lipidol. 2015 Mar-Apr; 9(2):201-9.
Score: 0,120